AWS' growth has trailed competitors so far, which was the biggest reason for the stock's underperformance for the last two years.
AWS growth is expected to reach 25% next year, and e-commerce and digital advertising are also expected to accelerate as the Fed will keep cutting rates.
The stock is trading near its lowest multiples despite the decades of runway for robust growth.
Marketplace is still growing 38% YoY, but I think the real star is its fintech business.
Fintech now makes up 43% of all revenue, and it's expected to surpass e-commerce in the next 2-3 years.
As a result, margins will significantly expand, and its moat will get even stronger as its fintech-marketplace ecosystem will lock in both merchants and customers.
Given that both of its businesses are growing above 30% YoY with years of runway ahead, 10x 2030 earnings is just criminally undervalued.
3. $PGY
5-year Revenue CAGR: 80%
Forward P/E: 15
ROIC: 8%
AI-powered lending infrastructure connecting banks with institutional investors, now the leading US personal loan ABS issuer.
Its valuation is depressed as investors are worried about markdowns on the loans it carries on its balance sheet; however, we saw in the last two quarters that markdowns are normalizing.
Thus, I believe the company is significantly derisked, though the market is yet to recognize this.
It's trading at 15x next year's earnings on around 20% expected growth. I think the market will bump up the multiple to at least 20x if we see further normalization in markdowns.
It's the largest and most profitable health insurer in the US, thanks to its vertical integration.
Its profitability took a significant hit this year due to higher-than-expected medical inflation and morbidity, but it's set a rebound for the next year as it significantly raised prices.
Legendary CEO Stephen Hemsley is back at the helm, and he is guiding for growth next year.
Compounder with a giant moat trading at attractive levels.
It created the whole obesity drug market with Ozempic and Wegovy, but the stock is depressed as investors are concerned about competition from $LLY and compounders.
Though the competition is serious, $NVO has a very strong pipeline in weight-loss and a few catalysts ahead.
It's expecting FDA approval for its oral Wegovy in the next 30 days, which will be the first GLP-1 pill on the market.
The market currently assumes only 7% growth for the next 10 years. It can do way better than this.
Amazon's biggest problem was the underperformance of AWS relative to its peers like Google Cloud and Microsoft Azure; this is changing now.
AWS growth reaccelerated to over 20% last quarter, and it's expected to hit over 25% in the coming quarters as Anthropic's two gigawatt-scale data centers started operation.
The stock had climbed above $250 levels after earnings due to strong AWS performance, but it's now back where it was before earnings.
I'll keep observing and add to my position if it drops below $200.